Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503673 | 0.78 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL2793986 | 0.78 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL18493703 | 0.78 | HSD11B1 (0.67) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL1787432 | 0.78 | HSD11B1 (1.00) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL660425 | 0.77 | HSD11B1 (0.48) | HSD11B1P2RX7CYP2C9EPHX2L3MBTL1 | |
| SCHEMBL11724444 | 0.77 | HSD11B1 (0.36) | HSD11B1CYP2C9HSD17B10ALDH1A1 | |
| SCHEMBL24507606 | 0.76 | HSD11B1 (0.52) | HSD11B1P2RX7CYP2C9 | |
| SCHEMBL11781373 | 0.76 | HSD11B1 (0.52) | HSD11B1P2RX7CYP2C9EPHX2ALDH1A1 | |
| SCHEMBL2093413 | 0.76 | HSD11B1 (0.47) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL11151720 | 0.76 | HSD11B1 (0.57) | HSD11B1P2RX7EPHX2L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316143-A1 | Ophthalmic composition | SOLL DAVID B (US) | 2012-12-13 | — | — | US | claimed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| EP-2163543-B1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8344181-B2 | Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-01 | — | — | US | disclosed |
| EP-1846363-B1 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010009389-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-13 | — | — | US | disclosed |
| US-7105310-B1 | Detection of biomolecules by sensitizer-linked substrates | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2006024627-A2 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050192358-A1 | Drugs for treating viral infections | GEORGIEV VASSIL S (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1513825-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Department of Health and Human Services (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
| US-6596771-B2 | Imidodisulfamide derivatives | SCHERING CORPORATION | 2003-07-22 | — | — | US | disclosed |
| US-20020193443-A1 | Drugs for treating viral infections | SCHERING CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-20020132851-A1 | DRUGS FOR TREATING VIRAL INFECTIONS | GEORGIEV VASSIL STEFANOV (US) | 2002-09-19 | — | — | US | disclosed |
| US-6433016-B1 | CARBOCYCLIC IMIDODISULFAMIDE DERIVATIVE VIRICIDES FOR ORTHOPOXVIRUSES | GEORGIEV VASSIL STEFANOV (US) | 2002-08-13 | — | — | US | disclosed |
| WO-2001006260-A1 | DETECTION OF BIOMOLECULES BY SENSITIZER-LINKED SUBSTRATES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885P2RX7 3609/4885CYP2C9 164/4885 |
| US-20050192358-A1 | Drugs for treating viral infections | ITPA, MAVS, PPIP5K2 | HSD11B1 4623/4885P2RX7 315/4885CYP2C9 3208/4885 |
| US-20020132851-A1 | DRUGS FOR TREATING VIRAL INFECTIONS | EIF2AK2, MAVS, SORD | HSD11B1 3104/4885P2RX7 938/4885CYP2C9 1894/4885 |
| US-20020193443-A1 | Drugs for treating viral infections | EIF2AK2, MAVS, DDX5 | HSD11B1 4473/4885P2RX7 302/4885CYP2C9 2284/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | HSD11B1 836/4885P2RX7 1356/4885CYP2C9 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.